Condition (MeSH)
Hyperkeratosis, Epidermolytic
ClinicalTrials.gov lists 4 trials for Hyperkeratosis, Epidermolytic or a narrower condition beneath it. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
4 of the 4 trials are tagged with Hyperkeratosis, Epidermolytic itself; the rest are tagged with a narrower condition beneath it.
When did Hyperkeratosis, Epidermolytic trials start? (3)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 2
- Not applicable
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2016 | 1 |
| 1994 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 4 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hyperkeratosis, Epidermolytic trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Not applicable | 1 |
| Observational | 1 |
How many Hyperkeratosis, Epidermolytic trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Completed | 3 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hyperkeratosis, Epidermolytic trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 1 |
Which serious adverse events do Hyperkeratosis, Epidermolytic trials report? (2)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hospitalization-GERD | 2 | 1 |
| Hospitalization-pyelonephritis | 1 | 1 |
Which publications cover Hyperkeratosis, Epidermolytic? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Histopathologic characterization of epidermolytic hyperkeratosis: a systematic review of histology from the National Registry for Ichthyosis and Related Skin Disorders. | Journal of the American Academy of Dermatology | 2008 | Yes |
| Genetic heterogeneity in erythrokeratodermia variabilis: novel mutations in the connexin gene GJB4 (Cx30.3) and genotype-phenotype correlations. | The Journal of investigative dermatology | 2003 | Yes |
| Epidermolytic hyperkeratosis: applied molecular genetics. | The Journal of investigative dermatology | 1994 | Yes |
| Keratins and skin disorders. | The Journal of pathology | 2004 | No |
Prevalence (10)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Autosomal dominant epidermolytic ichthyosis | Point prevalence | 1-9 / 1 000 000 | United States | US | Exact |
| Autosomal dominant epidermolytic ichthyosis | Point prevalence | 1-9 / 1 000 000 | United States | US | Exact |
| Autosomal dominant epidermolytic ichthyosis | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Autosomal dominant epidermolytic ichthyosis | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Autosomal dominant epidermolytic ichthyosis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Showing 5 of 10 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Autosomal dominant epidermolytic ichthyosis | 312 | Exact | Orphadata Science knowledge files, Product 1 |
| Autosomal dominant epidermolytic ichthyosis | 312 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.